We all know that pricing for prescription drugs can be all over the map. Regulators have tried a number of mechanisms to ensure that publicly-funded health programs don’t pay more than they have to. The Government Accounting Office looked at prices paid by three large government programs–Medicare, Medicaid and the Department of Defense health benefits plan. These plans cover over 114 million beneficiaries at a cost of about $71.2 billion in drug spending. (GAO Report) Using data from 2010 for drugs dispensed by retail pharmacies, which includes mail dispensing, the Agency selected 50 high price drugs and the 50 highest utilized medications, which after overlap, left 78 drugs, 33 of which were brands and 45 generics. The researchers ascertained both gross unit prices–the amount paid by the programs and the beneficiaries, and net unit prices–only what the programs paid. As might be expected, Medicaid paid the lowest net price per unit, at 62 cents across all the studied drugs, while Medicare Part D paid 82 cents a unit (32% higher) and the DOD paid 99 cents (60% more). And note that for Medicaid, GAO only used mandatory federal rebates and did not include any supplemental state refunds, which would have made the net Medicaid unit prices even lower. Gross prices were more dispersed across the programs, with Medicare having the lowest gross unit prices, while Medicaid was next and DOD quite a bit higher. But DOD had the lowest unit gross prices for brands, while Medicaid did for generics. Medicaid had the lowest net prices for brand drugs and generic drugs, while DOD paid 34% more for brands and 50% more for generics and the Part D plans paid 69% more for brands but only 4% more for generics. On an individual drug basis, however, some interesting differences are revealed. Medicaid paid the lowest net price for 25 brands and 3 generics, DOD paid the lowest for 5 brands and 22 generics and the Part D plans for 3 brands and 20 generics. Medicaid gets far higher rebates or post-purchase adjustments than did the other programs, which accounts for most of the difference in net unit prices. Medicaid’s rebates are generally statutory, which raises the question of why they haven’t been extended at least to the DOD program, and potentially made available to the Medicare Part D plans. The drug companies make money even on Medicaid prescriptions, so it is not clear what the rationale is for letting taxpayers pay more for DOD and Medicare drugs than they do for Medicaid ones. The data also demonstrate the power of a competitive market, with the Part D plans able to obtain good prices on generics but limited rebates on brand names, in part because Congress and CMS insist that they must have multiple drugs in all therapeutic categories and all drugs in a few. Removing that restriction would increase the negotiating leverage of the Part D plans.
Comparative Drug Prices
By Kevin RocheJuly 24, 2014Commentary
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
For those who would like to read more on the crisis of fake and bad science, read this excellent report from the National Association of Scholars. just click this post.
June 4, 2023
CVS has finalized its $10.6 billion buyout of Oak Street health, which operates primary care centers for Medicare members. People may think CVS is a drug store company, but it...
May 4, 2023
Option Care, a large home health care provider is acquiring Amedisys, another large player in that market, for $3.6 billion, as consolidation ramps up across health care, likely meaning higher...
May 4, 2023
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace
June 8, 2023
Yet Another Comprehensive Look at Lockdowns
Another major report finds that lockdowns had very little efficacy, in regard to infections or…
June 7, 2023
More and More on Jobs Reports
More BLS machinations around jobs numbers, this time in regard to seasonal adjustments.
June 7, 2023
Me on a Podcast
Your opportunity to see and hear me, courtesy of the Michele Tafoya podcast.